Bright Minds Biosciences Inc
Research Bright Minds Biosciences Inc (DRUG) on Bullrun: market cap USD 784.10M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerDRUG
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 784.10M
- Financial periodQ1 2026
- RevenueCAD 0
- Net income-CAD 27.35M
- Free cash flow-CAD 9.25M
Valuation Snapshot
latest market cap is USD 784.10M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CAD 0 | -CAD 19.84M | -CAD 13.01M | n/a | -3.91 | CAD 89.05M | CAD 104.90K | CAD 89.28M |
| FY2024 | CAD 0 | -CAD 1.07M | -CAD 2.52M | n/a | -0.72 | CAD 57.90M | CAD 182.73K | CAD 57.83M |
| FY2023 | n/a | n/a | n/a | n/a | -3.35 | CAD 6.76M | CAD 54.56K | CAD 6.03M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 784.10M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 607.71M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 251.74M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 6.38M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 13.85M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 37.55M | n/a | n/a | n/a |
About Bright Minds Biosciences Inc
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Bright Minds Biosciences Inc's market cap?
Bright Minds Biosciences Inc's market capitalization is USD 784.10M.
What does Bright Minds Biosciences Inc do?
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.